| Testing considerations for novel cell substrates: a regulatory perspective. | |
| | |
MedLine Citation:
|
PMID: 21502046 Owner: NLM Status: In-Data-Review |
Abstract/OtherAbstract:
|
The development of new products for the prevention and treatment of current as well as emerging and re-emerging diseases has led to the introduction of novel cell substrates in biologics. Examples include the demand for large-scale production of pandemic influenza vaccines and for therapeutic proteins, and the use of novel vectors for AIDS vaccines and in cancer gene therapy. A major safety issue regarding the use of novel cell substrates is adventitious agents, including viruses that may have been exogenously introduced due to cell passage history or indigenous viruses that are naturally occurring in the species of cell origin due to infection, or endogenous retroviruses that exist as a normal part of the host cell DNA. Additionally, in the case of genetically engineered cells, there is a concern for recombinant viruses that may be generated de novo involving vector virus sequences. Furthermore, potential oncogenicity of residual cellular DNA remains a theoretical safety concern related to tumorigenic cell substrates. This paper discusses safety issues related to novel cell substrates with a focus on tumorigenic cells and genetically engineered cells and presents the current testing recommendations for general cell substrate safety with details on additional assays for consideration in testing some novel cell substrates including tumorigenic cells. |
| | |
Authors:
|
A S Khan |
Related Documents
:
|
15356656 - Farnesyltransferase inhibitor bms-214662 induces apoptosis in b-cell chronic lymphocyti... 12417326 - Selective cyclooxygenase-2 inhibitors show a differential ability to inhibit proliferat... 15884096 - High-resolution magic-angle-spinning 1h nmr spectroscopy reveals different responses in... 19341726 - Association of early phase of colorectal carcinogenesis with stat3 activation and its r... 11261586 - Lipophilization of somatostatin analog rc-160 with long chain fatty acid improves its a... 15290716 - Proliferative response of bystander cells adjacent to cells with incorporated radioacti... |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: PDA journal of pharmaceutical science and technology / PDA Volume: 64 ISSN: 1079-7440 ISO Abbreviation: PDA J Pharm Sci Technol Publication Date: 2010 Sep-Oct |
Date Detail:
|
Created Date: 2011-04-19 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9439538 Medline TA: PDA J Pharm Sci Technol Country: United States |
Other Details:
|
Languages: eng Pagination: 426-31 Citation Subset: IM |
Affiliation:
|
Division of Viral Products, Office of Vaccines Research and Review, Center for Biologics Evaluation and Research, U.S. Food and Drug Administration, Bethesda, MD, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: The Avian EB66(R) Cell Line, Application to Vaccines, and Therapeutic Protein Production.
Next Document: Gamma-irradiation of serum for the inactivation of adventitious contaminants.